Cannabis Law and Access in Switzerland

Switzerland runs a different experiment to the rest of Europe

Forty-one countries, one small Alpine nation, and a regulatory framework that keeps catching researchers off guard. Switzerland is not the Netherlands. It is not Germany. And it is emphatically not a free market , but it has spent the last decade stress-testing a more pragmatic approach to cannabis regulation than most of its neighbours have been willing to try.

I've been watching this play out for a few months in the context of a broader project on how non-EU jurisdictions handle cannabinoid scheduling. Switzerland sits outside the European Union, which gives it unusual room to move on controlled substances without needing Brussels to sign off first. That independence shows in the detail.

This article covers Swiss law as it stands. None of it describes Australian law, and nothing here should be read as advice on accessing, importing or obtaining cannabis or cannabinoid products in Australia. For how that works here, the TGA's framework , including the Special Access Scheme and the Authorised Prescriber pathway , governs everything.

The legal backbone: the Narcotics Act and the 2021 threshold shift

Swiss drug law sits primarily in the Betäubungsmittelgesetz (BetmG); the Federal Act on Narcotics and Psychotropic Substances. Cannabis with a THC content above 1% has historically been classified as a narcotic under that Act, making cultivation, supply and possession for non-medical purposes illegal.

The headline change came in 2021 when Switzerland lowered its THC threshold for "hemp", from the old 0.3% figure that had applied in agricultural contexts to a working standard aligned with its broader narcotics definition. More significantly, the revised Narcotics Act amendments that came into force in stages around 2021–2024 created a formal framework for cannabis pilot trials. These are city-level, research-linked programmes allowing limited adult-use cannabis sales to enrolled participants, with academic oversight and strict supply chain controls.

Basel was among the first Swiss cities to launch one of these pilots. Zurich and Bern followed. The pilots are not legalisation, they are time-limited, enrolment-based research exercises, and participation requires registration. Selling outside the scheme remains a criminal matter.

Low-THC cannabis: the "CBD flower" grey zone that became a grey market

Here's where it gets genuinely interesting from a regulatory architecture standpoint. Switzerland became, somewhat by accident, a notable early producer and exporter of low-THC cannabis; what most Europeans call "CBD flower", in the mid-2010s. Products with THC content below 1% were not classified as narcotics under Swiss law, and cannabidiol itself was not specifically scheduled.

This created a window. Swiss-grown low-THC flower flooded domestic markets and spilled across borders into countries with stricter rules. Germany, Austria, and Italy spent years trying to work out whether these products were tobacco substitutes, novel foods, or something else entirely. Switzerland watched with the detached calm of a country that had already made its regulatory call.

The domestic picture for CBD products is now reasonably settled. Products derived from hemp with THC below 1% can be sold in Switzerland without narcotics classification, though they must comply with food law, cosmetics law or tobacco regulations depending on the form. A CBD oil marketed as a food supplement is a food product under Swiss law, it does not carry a therapeutic claim by default, and it is not classified as a medicine unless positioned as one.

That distinction matters enormously. In Australia, the ARTG and TGA scheduling sit at the centre of how cannabidiol products are classified; low-dose CBD is a Schedule 3 pharmacist-only medicine, higher-dose products are Schedule 4 or Schedule 8 depending on THC content and dose. Switzerland does not have a direct equivalent of that consumer-level downscheduling step; the pathways diverge considerably from there.

Medical cannabis: the prescription pathway

Medical cannabis in Switzerland operates under an exemption framework within the BetmG. Cannabis-based medicines with THC above the 1% threshold require a cantonal exemption (an Ausnahmebewilligung) issued by the Federal Office of Public Health (FOPH, Bundesamt für Gesundheit, or BAG in German). Prescribing physicians must apply for this exemption on a per-patient basis, and the products supplied must meet quality standards consistent with pharmaceutical-grade manufacturing, something that maps loosely to what we'd call Good Manufacturing Practice requirements here.

Prior to 2022, these exemptions were theoretically available but bureaucratically difficult. A revision to the Narcotics Ordinance in 2022 streamlined the exemption process, allowing physicians to prescribe cannabis-based medicines with fewer procedural hurdles; still not a standard script, but considerably less laborious than before.

Switzerland also permits the prescription of authorised cannabis medicines where they exist (including Sativex, which holds a marketing authorisation in Switzerland for specific indications under its approved label).

The pilot trials: what they are and are not

I want to be precise here, because the pilots get misreported pretty consistently. The Swiss Parliament amended the BetmG specifically to allow these time-limited research programmes. They are not a soft legalisation. They are not dispensaries. They are scientific studies with ethics approval, enrolment criteria, outcome tracking, and defined end dates, operating under Article 8a of the revised Act.

Participants receive cannabis through the trial supply chain, not through retail. Researchers track data on consumption patterns, health indicators, and behaviour. The explicit purpose is to generate evidence that informs future policy, a bit like a randomised-controlled framework for drug policy itself. Whether that evidence will eventually push Switzerland toward broader reform depends on what the data shows, and on a political climate that remains genuinely divided on the question.

I'll be honest: I reckon the pilot model is one of the more intellectually honest approaches to cannabis reform in the world right now. Most jurisdictions either ban outright or legalise commercially. Running a structured research programme before committing either way is methodologically defensible, even if it is frustratingly slow for advocates.

Hemp, terpenes, and what actually crosses the border

Swiss hemp cultivation for fibre and seed has a long agricultural history; and modern Swiss hemp production increasingly includes aromatic cultivars grown for their terpene profiles and cannabinoid content, provided THC stays under the legal threshold. The phytochemical complexity of these plants, including the interaction between CBD, minor cannabinoids, and terpenes like beta-caryophyllene and myrcene, is an active area of botanical research. The question of whether full-spectrum extracts behave differently to isolates at a pharmacological level is one Switzerland's academic institutions have been quietly investigating for some years.

None of that research output changes what is or isn't legal to bring into Australia. Importing any cannabis product into Australia, regardless of where it originates or what its THC content is, requires TGA approval. There are no exceptions for personal use importation of cannabis-derived products.

I was flicking through a vintage Swiss cantonal survey map I picked up in Bern a few years back; it predates the hemp revival entirely and marks the old flax-growing valleys. The continuity of fibre cultivation in those same valleys now producing modern CBD cultivars is a neat historical thread, if you're into that kind of thing.

What Australian readers should take from the Swiss model

Switzerland demonstrates that there is no single "European" approach to cannabis, the legal architecture varies substantially country by country, and Switzerland's non-EU status gives it genuine flexibility. The pilot trial model is being watched by researchers globally, including in Australia, where the TGA and state-level authorities track international regulatory developments as part of their own evidence-gathering.

For Australians curious about how cannabis is accessed lawfully here, the pathways are the Special Access Scheme, the Authorised Prescriber scheme, and clinical trials registered under the relevant ethics frameworks. These are meaningfully different from the Swiss exemption model, but both reflect an underlying logic: structured, documented access with oversight, rather than an unregulated free market.

The scheduling detail for Australian products, covering both THC-dominant and CBD-dominant preparations; sits across Schedule 4 and Schedule 8 of the Poisons Standard, with the 2021 rescheduling of low-dose CBD as Schedule 3 being the most recent consumer-facing shift. Understanding where a given product sits in that framework is always the starting point.

Sources

• Cannabis, Federal Office of Public Health (FOPH), Switzerland
• Medicinal Cannabis: Guidance documents and information, Therapeutic Goods Administration (TGA)
• Cannabis pilot trials in Switzerland: design and rationale; NCBI/PubMed Central
• Cannabis and the law, Alcohol and Drug Foundation (ADF)

, Marcus Hale, Regulatory researcher, TGA & access law